| Disease ID | Disease name | Reference |
|---|
| MESH:C538458 |
Rapidly progressive glomerulonephritis with pulmonary hemorrhage |
PMID:16207324 |
| MESH:C572845 |
Thyroid cancer, follicular |
PMID:4758968 |
| MESH:D000014 |
Abnormalities, Drug-Induced |
PMID:16440566 |
| MESH:D000068079 |
Motor Disorders |
PMID:27413119 |
| MESH:D000230 |
Adenocarcinoma |
PMID:4758968 |
| MESH:D000236 |
Adenoma |
PMID:16942904; PMID:4758968 |
| MESH:D000370 |
Ageusia |
PMID:7076071 |
| MESH:D000380 |
Agranulocytosis |
PMID:12232461; PMID:15072706; PMID:16553037; PMID:18816182; PMID:20144635; PMID:2523194; PMID:4172680 |
| MESH:D000741 |
Anemia, Aplastic |
PMID:10085704; PMID:10544668; PMID:15072706; PMID:15493589; PMID:1642096; PMID:16553037; PMID:171299; PMID:18816182; PMID:20144635; PMID:3437520; PMID:6188311; PMID:9086574; PMID:9245107; PMID:9777751 |
| MESH:D000857 |
Olfaction Disorders |
PMID:639655; PMID:8838641 |
| MESH:D001168 |
Arthritis |
PMID:15785249 |
| MESH:D001724 |
Birth Weight |
PMID:29990518; PMID:34757178 |
| MESH:D002277 |
Carcinoma |
PMID:16942904 |
| MESH:D002754 |
Choanal Atresia |
PMID:11745832; PMID:16440566 |
| MESH:D002779 |
Cholestasis |
PMID:12467281; PMID:17724899; PMID:20960257; PMID:2271514; PMID:34788025 |
| MESH:D002780 |
Cholestasis, Intrahepatic |
PMID:19534646; PMID:20707932; PMID:3804181; PMID:4641547; PMID:8817448 |
| MESH:D003875 |
Drug Eruptions |
PMID:20168071 |
| MESH:D004195 |
Disease Models, Animal |
PMID:27421576 |
| MESH:D004342 |
Drug Hypersensitivity |
PMID:3405562; PMID:6188311 |
| MESH:D004476 |
Ectodermal Dysplasia |
PMID:11038449 |
| MESH:D004844 |
Epistaxis |
PMID:15493589 |
| MESH:D004933 |
Esophageal Atresia |
PMID:11745832 |
| MESH:D005076 |
Exanthema |
PMID:15785249; PMID:20168071; PMID:2523194; PMID:9773944 |
| MESH:D005221 |
Fatigue |
PMID:15493589 |
| MESH:D005334 |
Fever |
PMID:15785249 |
| MESH:D005767 |
Gastrointestinal Diseases |
PMID:2523194 |
| MESH:D005921 |
Glomerulonephritis |
PMID:8956314 |
| MESH:D006042 |
Goiter |
PMID:20036711 |
| MESH:D006406 |
Hematoma |
PMID:15493589 |
| MESH:D006470 |
Hemorrhage |
PMID:11802538; PMID:16553037 |
| MESH:D006505 |
Hepatitis |
PMID:1937386 |
| MESH:D006529 |
Hepatomegaly |
PMID:28108177 |
| MESH:D006932 |
Hyperbilirubinemia |
PMID:14982270 |
| MESH:D006965 |
Hyperplasia |
PMID:4758968 |
| MESH:D006980 |
Hyperthyroidism |
PMID:27413119 |
| MESH:D006984 |
Hypertrophy |
PMID:4758968 |
| MESH:D006996 |
Hypocalcemia |
PMID:1657745 |
| MESH:D007003 |
Hypoglycemia |
PMID:29990518 |
| MESH:D007035 |
Hypothermia |
PMID:26177832 |
| MESH:D007037 |
Hypothyroidism |
PMID:11521740; PMID:12587721; PMID:1387618; PMID:18031379; PMID:20808432; PMID:21314467; PMID:25539664; PMID:8921835 |
| MESH:D007565 |
Jaundice |
PMID:12467281 |
| MESH:D007805 |
Language Development Disorders |
PMID:16440566 |
| MESH:D007859 |
Learning Disabilities |
PMID:27413119 |
| MESH:D007970 |
Leukopenia |
PMID:20144635; PMID:8548997 |
| MESH:D008107 |
Liver Diseases |
PMID:18383979 |
| MESH:D008181 |
Lupus Nephritis |
PMID:14723259 |
| MESH:D009069 |
Movement Disorders |
PMID:3754623 |
| MESH:D009120 |
Muscle Cramp |
PMID:1657745 |
| MESH:D009157 |
Myasthenia Gravis |
PMID:1798220; PMID:20635587 |
| MESH:D009336 |
Necrosis |
PMID:27421576 |
| MESH:D009404 |
Nephrotic Syndrome |
PMID:434980 |
| MESH:D010198 |
Pancytopenia |
PMID:15493589; PMID:6188311 |
| MESH:D011297 |
Prenatal Exposure Delayed Effects |
PMID:11745832; PMID:16440566; PMID:27413119; PMID:29990518; PMID:3754623 |
| MESH:D011507 |
Proteinuria |
PMID:434980 |
| MESH:D011537 |
Pruritus |
PMID:12467281; PMID:14982270; PMID:20960257 |
| MESH:D012640 |
Seizures |
PMID:11712661 |
| MESH:D012872 |
Skin Diseases, Vesiculobullous |
PMID:12353714 |
| MESH:D013064 |
Speech Disorders |
PMID:16440566 |
| MESH:D013651 |
Taste Disorders |
PMID:1245162; PMID:639655 |
| MESH:D013921 |
Thrombocytopenia |
PMID:15493589; PMID:20144635 |
| MESH:D013959 |
Thyroid Diseases |
PMID:21800831; PMID:34757178 |
| MESH:D013964 |
Thyroid Neoplasms |
PMID:16942904 |
| MESH:D013971 |
Thyrotoxicosis |
PMID:1657745 |
| MESH:D014581 |
Urticaria |
PMID:15785249 |
| MESH:D014657 |
Vasculitis |
PMID:16207347; PMID:8548997 |
| MESH:D015209 |
Cholangitis, Sclerosing |
PMID:8817448 |
| MESH:D015431 |
Weight Loss |
PMID:29990518; PMID:34757178 |
| MESH:D016171 |
Torsades de Pointes |
PMID:11707056 |
| MESH:D017093 |
Liver Failure |
PMID:20707932 |
| MESH:D017114 |
Liver Failure, Acute |
PMID:2271514 |
| MESH:D017563 |
Lung Diseases, Interstitial |
PMID:8956314 |
| MESH:D018366 |
Vasculitis, Leukocytoclastic, Cutaneous |
PMID:16207347 |
| MESH:D018476 |
Hypokinesia |
PMID:25962731 |
| MESH:D018771 |
Arthralgia |
PMID:15785249; PMID:16207347; PMID:2523194; PMID:505096 |
| MESH:D018908 |
Muscle Weakness |
PMID:505096 |
| MESH:D019465 |
Craniofacial Abnormalities |
PMID:16440566; PMID:25962731 |
| MESH:D020293 |
Vasculitis, Central Nervous System |
PMID:18788922 |
| MESH:D041781 |
Jaundice, Obstructive |
PMID:14982270; PMID:1687933; PMID:17493435; PMID:20960257 |
| MESH:D047508 |
Massive Hepatic Necrosis |
PMID:2484903 |
| MESH:D048550 |
Hepatic Insufficiency |
PMID:20960098 |
| MESH:D055953 |
Microscopic Polyangiitis |
PMID:16207324 |
| MESH:D056486 |
Chemical and Drug Induced Liver Injury |
PMID:1245162; PMID:12467281; PMID:17493435; PMID:17724899; PMID:20960098; PMID:22407903; PMID:2271514; PMID:24085192; PMID:2523194; PMID:26177832; PMID:27421576; PMID:28437613; PMID:29990518; PMID:33814510; PMID:34788025 |
| MESH:D056648 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis |
PMID:11802538; PMID:12353714; PMID:15175822; PMID:20061292 |
| MESH:D064420 |
Drug-Related Side Effects and Adverse Reactions |
PMID:434980 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.